Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1767649 | PMC |
| http://dx.doi.org/10.1136/heart.89.5.553 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dabigatran for left ventricular thrombus.
Indian Heart J
December 2016
Professor and Head of Cardiology, Department of Cardiology, Bombay Hospital Institute of Medical Sciences, Bombay Hospital, 12, New Marine Lines, Mumbai, Maharashtra 400 020, India.
Male patient in dilated phase of hypertrophic cardiomyopathy had multiple hospitalizations during the past 2 years either due to congestive heart failure, stroke, scar epilepsy, or atrial fibrillation and ventricular tachycardia. Medication included evidence based therapy for heart failure, cordarone and warfarin. Anticoagulation had to be discontinued due to marked fluctuations in INR.
View Article and Find Full Text PDFEffects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin concentrations in patients with non-valvar atrial fibrillation.
Heart
June 2005
Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK.
Objective: To examine further the relations of plasma von Willebrand factor (vWf, an index of endothelial damage and dysfunction) and soluble P-selectin (sP-sel, an index of platelet activation) concentrations to the presence and onset of clinical congestive heart failure (CHF) and the degree of left ventricular (LV) dysfunction in patients taking part in the SPAF (stroke prevention in atrial fibrillation) study.
Methods: Plasma concentrations of vWf and sP-sel were measured by enzyme linked immunosorbent assay (ELISA) in 1321 participants in the SPAF III study and related to the presence and onset of clinical CHF, as well as echocardiographic findings. Of the 1321 patients with atrial fibrillation (AF), 331 (25%) had a documented history of clinical heart failure, of which 168 cases were related to a new or recurrent episode of acute decompensated heart failure occurring within the preceding three months.
Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin.
Heart
February 2006
School of Medicine, Cardiff University, Cardiff, UK.
Objective: To compare survival and adverse outcome of patients with non-valvar atrial fibrillation (NVAF) treated with or without warfarin.
Design: Record linkage method to identify patients with a previous hospital diagnosis of atrial fibrillation and to link these patients to international normalised ratio (INR) test results and mortality data.
Setting: Cardiff and the Vale of Glamorgan, Wales.
Objective: To evaluate how well patients with non-valvar atrial fibrillation (NVAF) were maintained within the recommended international normalised ratio (INR) target of 2.0-3.0 and to explore the relation between achieved INR control and clinical outcomes.
View Article and Find Full Text PDF[Atrial fibrillation, stroke and anticoagulation: under-use of warfarin?].
Arq Neuropsiquiatr
December 2004
Universidade de Joinville, Joinville, SC, Brazil.
Objective: To correlate the presence of non valvar atrial fibrillation (NVAF) and cardioembolic stroke in patients previously assisted by cardiologists and without restrictions to the use of warfarin, with the level of acceptance of the recommendations published about chronic AF among these professionals.
Method: All strokes accepted in two hospitals of Joinville were prospectively recorded. The patients with AF were questioned about their previous knowledge about arrythmia, the frequency they had seen their cardiologists and the use of warfarin.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!